Every patient has a story 📖 Ina reminds us that patients know best what it means to live with a disease. Listening to their voices helps us create solutions that truly matter. 👇Meet Ina and discover her passion behind Belgian pharma. 📖Read the full Report to Society here: https://lnkd.in/eyMpBFGS #Report2Society #Patient #PassionForPharma pharma.be Ina Gesquiere
pharma.be
Pharmaceutical Manufacturing
pharma.be is the federation of 130+ innovative pharmaceutical companies active in Belgium.
About us
pharma.be, the federation of the innovative biopharmaceutical industry in Belgium, represents over 128 companies and 42.000 employees active in human healthcare in Belgium. As a full partner of physicians, pharmacists, hospitals, governments and other stakeholders, pharma.be has the mission to promote better health care through therapeutic innovation in the domain of medicinal products for human and veterinary use. Therefore, the top priority is to ensure that patients have the fastest possible access to innovative medicines resulting from research and development. Twitter: https://twitter.com/pharmabe and @CarolineVen Website: www.pharma.be
- Website
-
http://www.pharma.be
External link for pharma.be
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Brussels
- Type
- Nonprofit
- Founded
- 1966
- Specialties
- Pharmaceutical industry
Locations
-
Primary
Get directions
Canterstee 47
Brussels, 1000, BE
Employees at pharma.be
Updates
-
Interesting article this week in DH Les Sports +on the importance of gathering and sharing data. More info here: NL: https://lnkd.in/eUCvAX6Q FR: https://lnkd.in/eguRZqG2 Read the article: https://lnkd.in/ecqM4FAP #patients #patiënten #data #gezondheid #santé Ludovic Jimenez
-
Taking the right medicine, the right way 💊 Camille explains why taking medicines at the right time, in the right dose, and in the right way isn’t as obvious as it seems. Collaboration between industry, doctors, and pharmacists is key to better adherence. 👇Meet Camille and discover her passion of real people behind Belgian pharma. 📖Read the full Report to Society here: https://lnkd.in/eyMpBFGS #Report2Society #adherence #PassionForPharma pharma.be Camille Roelens
-
Meer #investeren in #diergezondheid. Dat is wat de wereldbankgroep voorstelt. Jaarlijks gaat wereldwijd 300 miljard dollar verloren aan #dierziekten. De meest #kosteneffectieve_oplossing is een jaarlijkse investering van 2,3 miljard dollar in diergezondheid om de kloof te dichten. Gezonde dieren, gezonde mensen. #Investir davantage dans la #santé_animale. C'est ce que propose le Groupe de la Banque mondiale. Chaque année, les #maladies_animales entraînent une perte de 300 milliards de dollars à l'échelle mondiale. La #solution_la_plus_rentable consiste à investir 2,3 milliards de dollars par an dans la santé animale afin de combler ce déficit. Des animaux sains, des humains sains. #OneHealth AnimalhealthEurope World Organisation for Animal Health health
$300 billion. That's the estimated annual cost of animal diseases to the global economy. So, how do we close this gap? In the latest episode of Time Out, The World Bank Group expert, Franck C.J. Berthe explains why investing in animal health is one of the most cost-effective solutions and can save billions. Catch the full conversation: https://lnkd.in/eRYdwg8U
The cost of animal health and how we can reduce it
-
Made in Belgium means excellence 💡 For Julie, “Made in Belgium” means top quality and world-class expertise. With more than 30 advanced sites across the country, we produce innovative medicines every day for patients around the globe. Beyond technology and innovation, it is the dedication of thousands of colleagues who give their best every day that makes the difference. 👇Meet Julie and discover her passion behind Belgian pharma. 📖Read the full Report to Society here: https://lnkd.in/ek6AiYqe #ReportToSociety #MadeInBelgium #PassionForPharma pharma.be Julie Rivière-Lorphèvre
-
Sciensano wil via het #onderzoeksproject CaDeCaD (Causes of Delay in Cancer Diagnosis), de #oorzaken #in_kaart_brengen waarom een #kankerdiagnose soms later wordt gesteld dan zou moeten. Om dit te realiseren roept de organisatie #patiënten, hun #naasten, #zorgverleners zowel uit de eerste als de tweede lijn op om deel te nemen aan een #enquête bestaande uit minder dan 10 vragen om #aanbevelingen te kunnen formuleren om het stellen van een #diagnose te versnellen. Dans le cadre du #projet_de_recherche CaDeCaD (Causes of Delay in Cancer Diagnosis), Sciensano souhaite #identifier les #raisons pour lesquelles un #diagnostic_de_cancer est parfois posé plus tardivement qu'il ne le devrait. Pour ce faire, l'organisation invite les #patients, leurs #proches et les #professionnels_de_santé, tant de premier que de deuxième recours, à participer à une #enquête comportant moins de 10 questions, afin de pouvoir formuler des #recommandations visant à accélérer la pose du #diagnostic.
⏳Why is cancer sometimes diagnosed later than it should be? Delays in cancer diagnosis can occur for many reasons, at different stages of the care pathway. Understanding these factors is key to improving timely diagnosis and patient outcomes. The CaDeCaD (Causes of Delay in Cancer Diagnosis) research project aims to identify the main causes of diagnostic delays to reduce them by collecting the experiences of patients, their relatives and caregivers, as well as primary and secondary healthcare professionals. Want to share your experience as a patient, relative, caregiver or healthcare professional ? Answer our short survey (fewer than 10 questions) and help shape recommendations to reduce diagnostic delays. 👉 https://lnkd.in/eCEU28_j 👉 https://lnkd.in/eZpXxcZH
-
-
Clinical research that makes a difference 🔬 Mieke reminds us that clinical studies change lives—and Belgium is among Europe’s leaders. But we can’t slow down. To keep our top position, we must move faster and innovate every day. 👇Meet Mieke and discover her passion of real people behind Belgian pharma. 📖Read the full Report to Society here: https://lnkd.in/eyMpBFGS #Report2Society #Clinicaltrials #PassionForPharma pharma.be Mieke Vancoillie
-
A behind-the-scenes look at the making the next episode of A Talk in the Park. We recently recorded a fascinating conversation with Pedro Facon on the future of healthcare, innovation and how we can prepare our health system for tomorrow's challenges. The full podcast will be released from the end of August onwards. Thanks Pedro, for the open and inspiring exchange! #ATalkInThePark #Healthcare #Innovation #LifeSciences
-
-
If you agree with Caroline Ven please join us by signing on https://lnkd.in/eTXzBYqQ NL: https://lnkd.in/e-nRAuNu FR: https://lnkd.in/e7fz5vzu #innovation #innovatie #health #België #Belgique
“𝗪𝗲 𝗺𝗼𝗲𝘁𝗲𝗻 𝗯𝗹𝗶𝗷𝘃𝗲𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗿𝗲𝗻 𝗶𝗻 𝗼𝗻𝘇𝗲 𝘄𝗲𝘁𝗲𝗻𝘀𝗰𝗵𝗮𝗽𝗽𝗲𝗹𝗶𝗷𝗸𝗲 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝘁𝗶𝗲.” België behoort al jaren tot de Europese top in biofarmaceutisch onderzoek en innovatie. Maar in een geopolitieke en economische context die snel verandert, is die positie niet vanzelfsprekend. In een gesprek met Caroline Ven, CEO van pharma.be en lid van de FEB Business & Society Council, hebben we het over de sterktes van het Belgische biofarmaceutische ecosysteem, de cruciale rol van universiteiten, de uitdagingen rond financiering en vermarkting, en de impact van wereldwijde verschuivingen op onze concurrentiepositie. Haar boodschap is helder: wie ook morgen het verschil wil maken, moet vandaag blijven investeren in onderzoek, talent en innovatie. Lees het volledige interview hier: https://lnkd.in/e6yTvbzB Foto: Ben Brolet
-